Kahn Swick & Foti, LLC notifies Erasca, Inc. investors of an August 10, 2026 deadline to seek lead plaintiff appointment in a securities class action lawsuit. The lawsuit, filed in the United States District Court for the Southern District of California, covers investors who purchased Erasca shares between January 14, 2025 and April 26, 2026. The complaint alleges that Erasca and certain executives failed to disclose that preclinical data for its ERAS-0015 product was based on improper comparisons to Revolution Medicines, Inc., exposing the company to patent and trade secret violation risks, and that defendants lacked a reasonable basis for positive statements about ERAS-0015. Investors who suffered losses may contact Lewis Kahn at 1-877-515-1850 or lewis.kahn@ksfcounsel.com for more information.
Erasca IncSecurities class action lawsuit alleging failure to disclose improper preclinical data comparisons and patent/trade secret risks.
Revolution Medicines Inc